Moderna COVID-19 Vaccine Confirmed to Be Highly Effective by FDA Ahead of Expected Approval
By HospiMedica International staff writers
Posted on 16 Dec 2020
Moderna, Inc.’s (Cambridge, MA, USA) COVID-19 vaccine is not only extremely effective, but could also reduce the spread of the novel coronavirus, according to a detailed analysis released by the Food and Drug Administration (FDA).Posted on 16 Dec 2020
The FDA's briefing document states that Moderna's mRNA-1273 COVID-19 vaccine is 94% effective at preventing symptomatic illness, assessed at least two weeks after two doses given 28 days apart, in the final analysis. The FDA analysis confirms Moderna’s earlier assessment of an efficacy rate of 94.1% for its COVID-19 vaccine in a trial of 30,000 people. However, the FDA found the vaccine to be less effective in older people, as it had a higher effectiveness of 96% in people aged between 18 to 65 years, as compared to 86% for people aged 65years and older.
Illustration
The FDA's analysis further supported authorization of Moderna's COVID-19 vaccine for emergency use as the agency noted that the vaccine has a "favorable safety profile" and "no specific safety concerns identified that would preclude issuance of an EUA."
Related Links:
Moderna, Inc.